Factors that predict Health-Related Q uality of Life in patients with relapsing -remitting multiple sclerosis

Abstract

Health-Related Q uality of Life (HRQ oL) research is gaining acceptance in the field of multiple sclerosis (MS). Little is known about what precipitates quality of life change. It was hypothesized that physical aspects of quality of life decline with worsening objective disease measures and psychosocial aspects remain relatively stable regardless of change in objective measures. These assumptions are tested using data from a Phase 3 study of relapsing -remitting MS patients treated with interferon b-1a and reassessed approximately eight years after study initiation. The Sickness Impact Profile (SIP) questionnaire is the generic quality of life measure used in this study. Three summary scores of the SIP (Physical, Psychosocial, and Total scores), Expanded Disability Status Scores, Multiple Sclerosis Functio nal C omposite, and Brain Parenchymal Fraction were determined at baseline, year 2, and after an average of 8.1 years from study entry. SIP data collected during a clinic visit were available from 137 of the original 172 participants. A ll objective indicators worsened by follow-up. SIP Physical and Total scores significantly worsened from baseline to follow-up. SIP Psychosocial showed nonsignificant worsening. Regression analysis indicated that final measures of SIP Physical and Total scores were most strongly associated with change in objective measures and follow-up SIP Psychosocial was most strongly related to earlier scores on the same measure.

Keywords

clinical trials multiple sclerosis outcomes assessment quality o f life Sickness Impact Profile

Get full access to this article

View all access options for this article.

References

Rudick R , Antel J , Confavreux C , Cutter G , Ellison G , Fischer J et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force . Ann Neurol 1997; 42: 379-382 .

Cutter GR , Baier ML , Rudick RA , Cookfair DL , Fischer JS , Petkau J et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure . Brain 1999; 122: 871-882 .

Miller DM , Rudick RA , Cutter G , Baier M , Fischer JS. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life . Arch Neurol 2000; 57: 1319-1324 .

Fischer JS , Rudick RA , Cutter GR , Reingold SC. The Multiple Sclerosis Functional Composite (MSFC) measure: an integrated approach to MS clinical outcomes assessment . Mult Scler 1999; 5: 244-250 .

Rudick RA , Cutter G , Baier M , Fisher E , Weinstock-Guttman B , Mass MK et al. Use of the Multiple Sclerosis Functional Composite in predicting disability in relapsing MS . Neurology 2001; 56: 1324-1330 .

Miller DM , Rudick RA , Cutter G , Baier M , Fischer JS. Clinical significance of the Multiple Sclerosis Functional Composite: relationship to patient-reported quality of life . Arch Neurol 2000; 57(9): 1319-1324 .

Damiano AM. Sickness Impact Profile: user’s manual and interpertation guide. Baltimore, MD: Johns Hopkins University , 1996. Ref type: serial (book, monograph).

Bergner M , Bobbitt RA , Carter WB , Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure . Med Care 1981; 19: 787-805 .

Goodkin DE , Hertsgard D , Seminary J. Upper extermity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests . Arch Phys Med Rehabil 1988; 69: 850-854 .

10.

Gronwall DMA. Paced auditory serial-addition task: a measure of recovery from concussion . Percept Mot Skill 1977; 44: 367-373 .

11.

Fischer JS , Jak AJ , Knicker JE , Rudick RA. Administration and scoring manual for the Multiple Sclerosis Functional Composite Measure (MSFC). National Multiple Sclerosis Society. New York: Demos , 1999. Ref type: serial (book, monograph).

12.

Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

13.

Fisher E , Cothern R , Tkach J , Masaryk T , Cornhill J. Knowledge-based 3D segmentation of MR images for quantitative MS lesion tracking . SPIE Med Imaging 1997; 3034: 19-25 .

14.

[published erratum appears in Ann Neurol 1996; 40: 480-480 ].

15.

Simon JH , Jacobs LD , Campion M , Wende K , Simonian N , Cookfair DL et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group [see comments] . Ann Neurol 1998; 43: 79-87 .

16.

Rudick RA , Fisher E , Lee JC , Simon J , Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group . Neurology 1999; 53: 1698-1704 .

17.

Gianino JM , York MM , Paice JA , Shott S. Quality of life: effect of reduced spasticity from intrathecal baclofen . J Neurosci Nurs 1998; 30: 47-54 .

18.

Petajan JH , Gappmaier E , White AT , Spencer MK , Mino L , Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis [see comments] . Ann Neurol 1996; 39: 432-441 .

19.

Zeldow PB , Pavlou M. Physical and psychosocial functioning in multiple sclerosis: descriptions, correlations, and a tentative typology . Br J Med Psychol 1988; 61: 185-195 .

20.

Freeman JA , Thompson AJ , Fitzpatrick R , Hutchinson M , Miltenburger C , Beckmann K et al. Interferon-beta-1b in the treatment of secondary progressive MS: impact on quality of life . Neurology 2001; 57: 1870-1875 .

21.

Ware JEJ , Kosinski M , Bayliss MS , McHorney CA , Rogers WH et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study . Med Care 1995; 33: AS264-AS279 .